Matricelf Receives FDA Feedback Supporting Key Elements of Proposed First in Human Clinical Trial for NewRal Spinal Cord Injury Program

FDA feedback supports the proposed patient population, single arm open label trial design, primary safety assessments and exploratory efficacy measures Written regulatory feedback provides guidance as Matricelf advances preparations toward a future IND submission for NewRal NESS ZIONA,...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.